cui1,cui2,relation,name1,name2,type1,type2,weight,predicate
C0013216,C0006826,NEG_AFFECTS,Pharmacotherapy,Malignant Neoplasms,topp,neop,2,NEG_AFFECTS_TOPPnafctNEOP
C0013216,C0007114,NEG_AFFECTS,Pharmacotherapy,Malignant neoplasm of skin,topp,neop,1,NEG_AFFECTS_TOPPnafctNEOP
C0013216,C0027627,NEG_AFFECTS,Pharmacotherapy,Neoplasm Metastasis,topp,neop,1,NEG_AFFECTS_TOPPnafctNEOP
C0013216,C0027651,NEG_AFFECTS,Pharmacotherapy,Neoplasms,topp,neop,1,NEG_AFFECTS_TOPPnafctNEOP
C0013216,C2239176,NEG_AFFECTS,Pharmacotherapy,Liver carcinoma,topp,neop,1,NEG_AFFECTS_TOPPnafctNEOP
C0013216,C2939419,NEG_AFFECTS,Pharmacotherapy,Secondary Neoplasm,topp,neop,1,NEG_AFFECTS_TOPPnafctNEOP
C0920425,C0596263,NEG_AFFECTS,cancer therapy,Carcinogenesis,topp,neop,1,NEG_AFFECTS_TOPPnafctNEOP
C4329656,C0027651,NEG_AFFECTS,Checkpoint Blockade Immunotherapy,Neoplasms,topp,neop,1,NEG_AFFECTS_TOPPnafctNEOP
